Company Encyclopedia
View More
name
HUXTAPI@EC2605A
19138.HK
News
View More

XtalPi Announces Strategic Senior Management Change

XtalPi Holdings Limited announced a strategic senior management change as CFO Mr. Tam Man Hong transitions to Hong Kong and International Development Adviser in January 2026. This move aims to enhance the company's business development in Hong Kong and international markets, focusing on sustainable growth, mergers and acquisitions, and establishing an incubation ecosystem. The appointment of the next CFO will be announced later. This change is expected to strengthen XtalPi's regional and global presence.

Tip Ranks·
HK
02228
-0.43%
Tip Ranks·
HK
02228
-0.43%

XtalPi CFO Tam Man Hong to Become Hong Kong and International Development Adviser

XtalPi Holdings Ltd. announced that CFO Tam Man Hong will step down on December 31, 2025, and become Hong Kong and International Development Adviser from January 1, 2026. He will also serve as a non-executive director for overseas subsidiaries. A new CFO will be announced later.

Reuters·
HK
02228
-0.43%
Reuters·
HK
02228
-0.43%

MIRXES partners with XTALPI to build an integrated diagnosis and treatment platform

MIRXES-B signed a memorandum of understanding with XTALPI to integrate genomics technology and AI drug discovery platforms, aiming to establish an AI-enabled integrated diagnosis and treatment platform for high-incidence cancers in Asia, particularly gastrointestinal cancers, and to develop early diagnosis and treatment solutions

AASTOCKS·
HK
02629
-1.02%
HK
02228
-0.43%
AASTOCKS·
HK
02629
-1.02%
HK
02228
-0.43%

Mirxes Holding Enters MoU With Xtalpi Holdings

MiRXES Holding Co Ltd :ENTERS MOU WITH XTALPI HOLDINGSCO AND XTALPI TO BUILD AI PLATFORM FOR ASIAN HIGH-INCIDENCE CANCERS, OTHERS

Reuters·
HK
02629
-1.02%
HK
02228
-0.43%
Reuters·
HK
02629
-1.02%
HK
02228
-0.43%

Mirxes Holding Co. Ltd. Signs MOU with XtalPi for AI-Driven Cancer Diagnosis and Intervention Platform

Mirxes Holding Co. Ltd. has signed an MOU with XtalPi Holdings Limited to develop an AI-driven platform for early cancer diagnosis and intervention, focusing on gastrointestinal cancers in Asia. This collaboration aims to integrate Mirxes' genomics technology with XtalPi's AI drug discovery platform, enhancing R&D capabilities and supporting Mirxes' growth and revenue diversification. The partnership's continuation is not guaranteed.

Reuters·
HK
02629
-1.02%
HK
02228
-0.43%
Reuters·
HK
02629
-1.02%
HK
02228
-0.43%
Posts
View More

$Recursion Pharmaceuticals(RXRX.US) $XTALPI(02228.HK) Google DeepMind CEO Demis Hassabis' latest podcast is 56 minutes long, and his core views on AI development, future directions, and social impact ...

$XTALPI(02228.HK) MM's money is also borrowed, so it can't keep going down indefinitely, because, from the data, it's clear that most of the chips are still with MM. Is this logic reasonable? From the...

$XTALPI(02228.HK) is not too bad. Considering this ridiculous Hong Kong and A-share market

$XTALPI(02228.HK) Have you had enough fun! I warn you! Great MM! 😌 Remember, we are family!

  • 0

$XTALPI(02228.HK) A trading volume of 180 million, this volume has reached the lowest possible level. A reversal must happen immediately, otherwise liquidity will completely dry up. The whole market i...

  • 0
© 2025 Longbridge｜Disclaimer